Bruce Wendel has served on the Board of Trustees of the American Folk Art Museum since 2021 and is a member of the Nominating and Governance Committee. He was the Chief Executive Officer and Vice Chairman of Abraxis BioScience, Inc. until its acquisition by Celgene in 2010. Prior to that from 2004 to 2006, he served as Executive Vice President of Corporate Development at American Pharmaceutical Partners Inc. (APP) until its acquisition by Fresenius Kabi Pharmaceuticals. Prior to joining AAP, Mr. Wendel served as Vice President, Business Development & Licensing for IVAX Corporation, where he completed IVAX Corporation’s acquisition of 3M’s European respiratory business. In 1988, Mr. Wendel began his 14 years with Bristol-Myers Squibb (BMS), where he served as in-house counsel, before shifting to business and corporate development from 1990 to 2002. Mr. Wendel served as BMS’ Vice President Corporate Development International Medicines, and led teams that completed several major acquisitions, divestitures, and alliances around the world. He also served in the legal departments of Playtex and Combe. Mr. Wendel holds a Juris Doctorate from Georgetown University Law School, where he was an Editor of Law & Policy in International Business, and a Bachelor of Science degree from Cornell University. He is on the Board of Directors of GT Biopharma, a NASDAQ biotechnology company.